-
Study Points to Promising Chemoimmunotherapy Strategy for Aggressive Stage III Non-Small Cell Lung Cancer
04 Jul 2025 12:40 GMT
… III Non-Small Cell Lung Cancer
Publication: JAMA Oncology
Corresponding … III non-small cell lung cancer that is considered difficult … with mutations in KRAS and STK11 or KRAS and KEAP1 did … stage III non-small cell lung cancer have limited treatment options. …
-
Mutagenic Forces Shaping Lung Cancer Genomes
03 Jul 2025 02:59 GMT
… mutations in the KRAS gene were identified … landscape of lung cancerheterogeneity of lung cancerinternational lung cancer studyKRAS mutations … lung cancerregional differences in lung cancer mutationstobacco-free lung cancer casestreatment-naive lung cancer …
-
CNS Surveillance and Management of Brain Metastases in Patients With KRAS G12C NSCLC
02 Jul 2025 13:43 GMT
… Metastases Management in KRAS G12C Patients Central … patients with KRAS G12C positive non–small cell lung cancer, presenting … CNS-penetrant targeted agents, KRAS G12C patients have limited … CNS response rates, while KRAS G12C inhibitors show approximately …
-
HotSpot Therapeutics Presents Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025
04 Jul 2025 15:10 GMT
… and survival, particularly in KRAS-driven colorectal cancer (CRC), … as other KRAS-driven cancers, including pancreatic and lung cancer. Leveraging … and regression in multiple KRAS-driven tumor models.
… CRC cell lines, outperforming KRAS, BCL2 and Bcl-xL …
-
Distinct Lung Adenocarcinoma-Associated Microbiota Are Associated with Inflammatory Immune Landscapes and Tumor Cell Proliferation via LCIIAR–ISG15 Regulatory Networks
04 Jul 2025 14:41 GMT
… model of lung adenocarcinoma with Kras mutation and p53 deletion significantly … Chlamydiae, Firmicutes, and Proteobacteria. Notably, lung tumors (LUAD and LUSC) exhibited greater … between the two lung cancers but fewer shared with non-lung cancers (Figure S2 …
-
Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress
03 Jul 2025 18:16 GMT
… June 3. Updates from competing KRAS initiatives that were given at … PDAC and non-small cell lung cancer (NSCLC. With the initiation of …
-
Building a BioCypher-Powered AI Agent for Biomedical Knowledge Graph Generation and Querying
03 Jul 2025 11:57 GMT
… ", "EGFR", "KRAS", "MYC", … ;: ["breast_cancer", "lung_cancer", "diabetes", …
-
Oncogene Inhibitor Market Analysis 2025 – Insights For Long-Term Investment & Planning
03 Jul 2025 10:48 GMT
… on research for lung cancer treatments, increased investment in kras and myc inhibitors … trends such as next-generation KRAS inhibitors, AI-driven drug discovery … Indication: Breast Cancer, Ovarian Cancer, Lung Cancer, Pancreas Cancer, Other Indications
4 …
-
FDA News Recap: Novel Drug Approvals in First Half of 2025
02 Jul 2025 18:04 GMT
… therapies in breast and lung cancer to groundbreaking advances in … Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade … -squamous non-small cell lung cancer (NSCLC) with high c … -positive non-small cell lung cancer
Background: Approval based on …
-
Molecular Targeted Therapy Market Analysis 2025 – Insights for Long-Term Investment & Planning
02 Jul 2025 09:17 GMT
… designed for adult patients with KRAS G12C-mutated metastatic colorectal cancer … , Topical, Intravenous
3 By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia …
About
© 1995-2025